Drug Trial Radar · NCT03594422
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Jul 11, 2018
Primary completion
Dec 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Ascentage Pharma Group Inc.Industry
- Sponsor type
- Industry
- Collaborators
- HealthQuest Pharma Inc.
- First posted
- Jul 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Solid Tumor, Adult
Interventions
HQP1351Drug
HQP1351 Orally, once every other day (QOD) for consecutive 4 weeks each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and toleranceTime frame: 30 days after the last dose of HQP1351
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Chinese PLA general hospital, Beijing, China
Beijing, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Sun-Yat Sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangdong general hospital
Guangzhou, Guangdong, China · Recruiting
Henan cancer hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital Tongji Medical College of Huazhong University of Science ang Technology
Wuhan, Hubei, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.